The human epidermal growth factor receptor 2 (HER2, ERBB2) has been identified as an oncogenic driver in non-small cell lung cancer (NSCLC), with approximately 3% of patients with NSCLC harboring heterogeneous HER2 aberrations [1, 2]. Here, ERBB2 is linked to non-small cell lung carcinoma.